Dental Intelligence vs Bristol Myers Squibb

Side-by-side comparison of AI visibility scores, market position, and capabilities

Bristol Myers Squibb leads in AI visibility (80 vs 52)
Dental Intelligence logo

Dental Intelligence

ChallengerHealthtech

Dental Practice Analytics

Practice analytics and patient engagement platform for dental offices helping DSOs and independents grow production. American Fork UT; founded 2016; connects to 100+ dental PMS systems;

AI VisibilityBeta
Overall Score
C52
Category Rank
#281 of 596
AI Consensus
88%
Trend
stable
Per Platform
ChatGPT
52
Perplexity
53
Gemini
50

About

Dental Intelligence is an American Fork, Utah-based dental practice analytics and patient engagement platform that helps dental offices, group practices, and dental support organizations (DSOs) analyze production data, identify growth opportunities, and improve patient engagement and retention. Founded in 2016, the company built its platform around a core insight: most dental practices generate enormous amounts of operational data in their practice management software but lack the tools to turn that data into actionable insights. Dental Intelligence connects to over 100 dental practice management systems—including Dentrix, Eaglesoft, OpenDental, and Carestream—and automatically analyzes key performance indicators including production per provider, case acceptance rates, recall effectiveness, hygiene reappointment rates, and collections performance.\n\nThe platform's patient engagement tools allow dental practices to automate appointment reminders, recall outreach, and reactivation campaigns for patients who are overdue for cleanings or who have unscheduled treatment plans. These engagement automations reduce the manual administrative burden on front desk staff while improving patient show rates and reducing last-minute cancellations that disrupt production schedules. Dental Intelligence's analytics layer surfaces the specific operational levers most likely to drive revenue growth for each practice—whether that is improving treatment plan acceptance, filling hygiene chairs more efficiently, or reducing same-day cancellations.\n\nDental Intelligence has found particular traction with multi-location DSO customers that need consistent performance analytics and benchmarking across dozens or hundreds of dental practices. The platform's DSO-tier dashboards allow regional managers and corporate leadership to compare location performance, identify underperforming practices, and replicate the operational practices of top performers. The company competes with Weave, Solutionreach, and Carestream Dental in the dental technology market, differentiating on the depth of its practice analytics and its broad integration with existing dental practice management systems.

Full profile
Bristol Myers Squibb logo

Bristol Myers Squibb

LeaderHealthcare Tech

Enterprise

Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.

AI VisibilityBeta
Overall Score
A80
Category Rank
#18 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
78
Gemini
80

About

Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).

Full profile

AI Visibility Head-to-Head

52
Overall Score
80
#281
Category Rank
#18
88
AI Consensus
83
stable
Trend
stable
52
ChatGPT
78
53
Perplexity
78
50
Gemini
80
48
Claude
84
52
Grok
77

Key Details

Category
Dental Practice Analytics
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Dental Intelligence
Dental Practice Analytics

Integrations

Only Bristol Myers Squibb
Bristol Myers Squibb is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.